There are four main studies under PHACS: SMARTT, AMP, AMP Up, and AMP Up Lite. See below for a description of each. To learn more or to obtain a fully copy of any protocol, please email PHACS Web Support.
SMARTT (Surveillance Monitoring for ART Toxicities Study) looks at uninfected children born to mothers with HIV. Many mothers with HIV take antiretroviral medications while pregnant so they don’t pass the virus on to their babies. The goal of SMARTT is to study the long-term safety of these medications for babies who were exposed to them in the womb or after birth.
SMARTT includes three different groups of uninfected youth born to mothers with HIV.
• The Static cohort enrolled 1,240 children. All of these children were under 12 years old when they first joined the study. We are no longer enrolling youth in this cohort.
• The Dynamic cohort has enrolled 2,656 children as of June 2017. The goal is to enroll up to 250 uninfected newborns born to mothers with HIV every year. We will continue enrolling babies in this study for as long as the study is open.
• The Young Adult cohort was opened in 2016.
AMP (Adolescent Master Protocol) looks at infected and uninfected adolescents. The goal of AMP is to learn more about the effects of living with HIV since birth. This study also looks at the long-term effects of taking antiretroviral medications as children with HIV grow up.
AMP follows both infected and uninfected youth who enrolled in AMP between the ages of 7 and 16. Although we continue to follow these youth, we are no longer enrolling youth in AMP. Enrollment numbers are:
- 451 youth with HIV
- 227 uninfected youth (as a comparison group)
AMP Up is a continuation of the AMP protocol. It looks at infected and uninfected young adults (18 and older). The study’s goal is to look at the specific issues that these teenagers may face as they age into adulthood. Participation in this study includes 3 clinic visits over the course of 6 years, a web-based data collection component where participants complete yearly online surveys and assessments, and yearly lab testing for sexually transmitted infections.
AMP Up began in early 2014. This study will enroll 850 young adults who are at least 18 years of age at enrollment as follows:
- 600 youth with HIV
- 250 uninfected youth (as a comparison group)
AMP Up Lite is a Lite version of AMP Up created in 2017. It shares similar objectives with AMP Up, but with less intensive data collection. AMP Up Lite enrolls perinatally HIV-infected young adults. In addition to opening at established PHACS sites, this study recruits from clinics and areas in the U.S. where AMP UP was not open to enrollment.